Q1 Earnings Forecast for Korro Bio Issued By HC Wainwright

Posted by on May 20th, 2026

Korro Bio, Inc. (NASDAQ:KRRO – Free Report) – Investment analysts at HC Wainwright issued their Q1 2027 earnings per share (EPS) estimates for Korro Bio in a research note issued on Tuesday, May 19th. HC Wainwright analyst M. Kapoor expects that the company will earn ($1.54) per share for the quarter. HC Wainwright currently has a “Buy” rating and a $15.00 target price on the stock. The consensus estimate for Korro Bio’s current full-year earnings is ($5.63) per share. HC Wainwright also issued estimates for Korro Bio’s Q2 2027 earnings at ($1.51) EPS, Q3 2027 earnings at ($1.55) EPS, Q4 2027 earnings at ($1.62) EPS and FY2027 earnings at ($6.23) EPS.

Korro Bio (NASDAQ:KRRO – Get Free Report) last released its earnings results on Thursday, May 7th. The company reported ($1.69) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.60) by ($0.09). Korro Bio had a negative return on equity of 117.86% and a negative net margin of 1,834.48%.

Several other research firms have also issued reports on KRRO. Cantor Fitzgerald lifted their price target on shares of Korro Bio from $21.00 to $22.00 and gave the stock an “overweight” rating in a research report on Friday, March 13th. Citigroup began coverage on shares of Korro Bio in a report on Monday. They set a “buy” rating and a $21.00 price target on the stock. Raymond James Financial upgraded shares of Korro Bio from a “market perform” rating to an “outperform” rating and set a $23.00 price objective on the stock in a research report on Friday, March 13th. Weiss Ratings restated a “sell (d-)” rating on shares of Korro Bio in a report on Wednesday, April 8th. Finally, Chardan Capital raised Korro Bio from a “neutral” rating to a “buy” rating and set a $15.00 target price for the company in a research report on Thursday, January 29th. Two analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Korro Bio currently has an average rating of “Moderate Buy” and an average price target of $16.71.

Read Our Latest Analysis on KRRO

Korro Bio Price Performance

NASDAQ KRRO opened at $9.15 on Wednesday. The company’s 50 day simple moving average is $12.31 and its 200 day simple moving average is $12.05. Korro Bio has a 12 month low of $5.20 and a 12 month high of $55.89. The company has a market capitalization of $131.87 million, a P/E ratio of -0.78 and a beta of 3.07.

Insider Buying and Selling at Korro Bio

In related news, major shareholder Forest Baskett purchased 207,100 shares of the stock in a transaction on Tuesday, March 10th. The shares were bought at an average price of $11.11 per share, for a total transaction of $2,300,881.00. Following the completion of the acquisition, the insider directly owned 1,297,893 shares in the company, valued at approximately $14,419,591.23. This trade represents a 18.99% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, major shareholder Paul Edward Walker acquired 207,100 shares of Korro Bio stock in a transaction dated Tuesday, March 10th. The stock was purchased at an average price of $11.11 per share, with a total value of $2,300,881.00. Following the completion of the purchase, the insider directly owned 1,297,893 shares of the company’s stock, valued at $14,419,591.23. The trade was a 18.99% increase in their position. The SEC filing for this purchase provides additional information. Insiders have acquired a total of 1,657,320 shares of company stock worth $18,412,560 in the last 90 days. Company insiders own 4.80% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the company. Russell Investments Group Ltd. acquired a new position in Korro Bio during the 3rd quarter worth $39,000. Wells Fargo & Company MN increased its stake in shares of Korro Bio by 45.5% in the fourth quarter. Wells Fargo & Company MN now owns 7,522 shares of the company’s stock worth $60,000 after purchasing an additional 2,352 shares during the period. Bank of New York Mellon Corp increased its stake in shares of Korro Bio by 15.2% in the first quarter. Bank of New York Mellon Corp now owns 21,730 shares of the company’s stock worth $246,000 after purchasing an additional 2,875 shares during the period. PNC Financial Services Group Inc. acquired a new position in shares of Korro Bio during the 3rd quarter worth about $140,000. Finally, Millennium Management LLC boosted its stake in Korro Bio by 1.8% during the 3rd quarter. Millennium Management LLC now owns 260,333 shares of the company’s stock valued at $12,467,000 after purchasing an additional 4,650 shares during the period. Institutional investors own 13.18% of the company’s stock.

About Korro Bio

(Get Free Report)

Korro Bio, Inc is a clinical-stage biotechnology company focused on harnessing advanced protein engineering and synthetic biology to develop novel enzyme therapies and live microbial therapeutics. The company’s proprietary platform integrates directed evolution, high-throughput screening and computational design to optimize biological catalysts for a wide range of applications. By combining machine learning with experimental biology, Korro Bio seeks to accelerate the discovery and development of next-generation treatments for rare genetic disorders and complex metabolic diseases.

The company’s pipeline features both engineered enzyme therapeutics and live biotherapeutics.

Featured Stories

Earnings History and Estimates for Korro Bio (NASDAQ:KRRO)

Receive News & Ratings for Korro Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Korro Bio and related companies with MarketBeat.com's FREE daily email newsletter.